The phase III SASCIA (NCT04595565) and ASCENT-5 (NCT05633654) ongoing clinical trials are testing sacituzumab govitecan, an ADC composed of a mAb against TROP-2 and SN38-topoisomerase I inhibitor, against physician’s choice treatment in patients with residual invasive disease post-neoadjuvant therapy in HER2-negative BC, as a single agent, and in TNBC, in combination with pembrolizumab. This evidence concerns the gene ERBB2 and breast cancer.